Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.1K
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

848
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
848
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.5K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.5K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.5K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

635
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
635
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

2.8K
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Lesion Morphology and Resection Strategy on Curative Outcomes in Colorectal Malignant Polyps.

Clinical colorectal cancer·2026
Same author

Colonic Leishmaniasis Mimicking a Malignant Stricture: Initial Presentation of Human Immunodeficiency Virus Infection - A Case Report.

GE Portuguese journal of gastroenterology·2026
Same author

Early identification of patients with steatotic liver disease: Prospective evaluation of attenuation coefficient as an add-on to B-mode ultrasound.

European journal of radiology·2026
Same author

Concordance Between Pan-Intestinal Capsule Endoscopy and Colonoscopy for the Detection and Characterization of Colonic Lesions: Post Hoc Analysis on the Impact of Colonic Transit Time.

Journal of gastroenterology and hepatology·2026
Same author

AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).

United European gastroenterology journal·2026
Same author

Exploring the chemical and biological interplay in phenanthroline-containing copper complexes.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·2026

Related Experiment Video

Updated: Apr 1, 2026

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K

Mucosal Healing in Ulcerative Colitis--When Zero is Better.

Pedro Boal Carvalho1, Francisca Dias de Castro2, Bruno Rosa2

  • 1Hospital Senhora da Oliveira - Guimarães, Rua dos Cutileiros, Creixomil, 4831-044, Guimarães, Portugal pedroboalcarvalho@chaa.min-saude.pt.

Journal of Crohn'S & Colitis
|October 7, 2015
PubMed
Summary
This summary is machine-generated.

Mayo endoscopic score 1 in ulcerative colitis (UC) patients indicates a higher risk of clinical relapse within 12 months compared to score 0. Achieving a score of 0 is crucial for defining mucosal healing in UC.

Keywords:
Mayo scoreUlcerative colitisinflammatory bowel diseasesmucosal healing

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Related Experiment Videos

Last Updated: Apr 1, 2026

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Endoscopy

Background:

  • Mucosal healing is a key treatment goal for ulcerative colitis (UC).
  • Assessing endoscopic healing is vital for predicting disease course.
  • Mayo endoscopic score (MES) is used to evaluate UC activity.

Purpose of the Study:

  • To compare clinical relapse rates at 12 months between UC patients with MES 0 and MES 1.
  • To determine if MES 1 is associated with an increased risk of relapse in UC.
  • To evaluate the significance of MES 0 as a target for mucosal healing.

Main Methods:

  • Retrospective study of UC patients in corticosteroid-free remission (2008-2013).
  • Inclusion criteria: complete colonoscopy with MES 0 or 1, and ≥1 year follow-up.
  • Clinical relapse defined as need for induction therapy, escalation, hospitalization, or surgery.

Main Results:

  • 138 UC patients included; 55.8% had MES 1.
  • Clinical relapse was significantly higher in MES 1 (27.3%) vs MES 0 (11.5%) patients (p=0.022).
  • MES 1 was the sole factor predicting relapse risk (OR 2.89, p=0.026), particularly in left-sided/extensive colitis.

Conclusions:

  • MES 1 is linked to a 3-fold increased risk of clinical relapse in UC patients compared to MES 0.
  • This association is pronounced in left-sided or extensive colitis.
  • Endoscopic MES 0 is recommended as the optimal endpoint for defining mucosal healing in UC.